Under the agreement, Mallinckrodt's U.S. sales force will sell the drug to its customer base of prescribers. Zogenix will continue to record all product revenues and will compensate Mallinckrodt based on a percentage of net sales from prescriptions generated. The agreement runs through June 2014.
"This agreement represents a key component of our growing pharmaceuticals business as we prepare to spin off from Covidien next year," said Mark Trudeau, president of Mallinckrodt. "[It] allows us to help patients who suffer from migraine manage its often-debilitating impact, as well as to build out our existing pain management franchise."
Sumavel DosePro is a needle-free delivery system for the treatment of acute migraines. The product was launched in January 2010, and sales have reached more than 129,000 prescriptions through March 2012.
Related Articles on Pain Management:50 Pain Management Physician Medical Directors
Experts Debate Use of Spinal Manipulation for Back Pain
New York Announces Prescription Drug Monitoring Plan